Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Healthtrust
Chinese Patent Office
Fish and Richardson
Dow
Cerilliant
Argus Health
Farmers Insurance
Moodys
Colorcon
Queensland Health

Generated: October 19, 2017

DrugPatentWatch Database Preview

Taiho Oncology Company Profile

« Back to Dashboard

What is the competitive landscape for TAIHO ONCOLOGY, and when can generic versions of TAIHO ONCOLOGY drugs launch?

TAIHO ONCOLOGY has one approved drug.

There are three US patents protecting TAIHO ONCOLOGY drugs.

There are forty-five patent family members on TAIHO ONCOLOGY drugs in twenty-two countries and four supplementary protection certificates in four countries.

Summary for Applicant: Taiho Oncology

International Patents:45
US Patents:3
Tradenames:1
Ingredients:1
NDAs:1

Expired Patents for Taiho Oncology

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Taiho Oncology
LONSURF
tipiracil hydrochloride; trifluridine
TABLET;ORAL207981-002Sep 22, 2015► Subscribe► Subscribe
Taiho Oncology
LONSURF
tipiracil hydrochloride; trifluridine
TABLET;ORAL207981-001Sep 22, 2015► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Taiho Oncology

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,799,783Method of administrating an anticancer drug containing .alpha., .alpha., .alpha.-trifluorothymidine and thymidine phosphorylase inhibitor► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Taiho Oncology Drugs

Country Document Number Estimated Expiration
New Zealand714090► Subscribe
World Intellectual Property Organization (WIPO)0056337► Subscribe
Australia772486► Subscribe
Japan5576591► Subscribe
TaiwanI362265► Subscribe
World Intellectual Property Organization (WIPO)2006080327► Subscribe
Mexico2015016986► Subscribe
HungaryS1700032► Subscribe
Denmark1849470► Subscribe
Taiwan200637562► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Taiho Oncology Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2017 00036Denmark► SubscribePRODUCT NAME: TRIFLURIDINE IN COMBINATION WITH TIPIRACIL OR A PHARMACEUTICALLY ACCEPTABLE SALT OF TIPIRACIL; REG. NO/DATE: EU/1/16/1096 20160427
2017000052Germany► SubscribePRODUCT NAME: TRIFLURIDIN IN KOMBINATION MIT TIPIRACIL ODER EINEM SALZ VON TIPIRACIL WIE TIPIRACIL-HYDROCHLORID; REGISTRATION NO/DATE: EU/1/16/1096 20160425
0889Netherlands► SubscribePRODUCT NAME: TRIFLURIDINE IN COMBINATIE MET TIPIRACIL OF EEN ZOUT VAN TIPIRACIL, ZOALS TIPIRACILHYDROCHLORIDE; REGISTRATION NO/DATE: EU/1/16/1096 20160427
2017024Lithuania► SubscribePRODUCT NAME: TRIFLURIDINAS/TIPIRACILAS; REGISTRATION NO/DATE: EU/1/16/1096 20160425
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Deloitte
Chinese Patent Office
Federal Trade Commission
McKinsey
UBS
Moodys
Baxter
QuintilesIMS
Farmers Insurance
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot